U.S. flag An official website of the United States government

On Oct. 1, 2024, the FDA began implementing a reorganization impacting many parts of the agency. We are in the process of updating FDA.gov content to reflect these changes.

U.S. Food and Drug Administration
  1. Home
  2. Drugs
  3. Development & Approval Process | Drugs
  4. Drug Development Tool (DDT) Qualification Programs
  5. Clinical Outcome Assessment (COA) Qualification Program
  6. DDT COA #000019: Skin Infection Patient-Reported Outcome Measure (SKINFECT-PRO)
  1. Clinical Outcome Assessment (COA) Qualification Program

DDT COA #000019: Skin Infection Patient-Reported Outcome Measure (SKINFECT-PRO)

Clinical Outcome Assessments (COA) Qualification Submissions
Office of Infectious Diseases (OID)
Division of Anti-Infectives (DAI)

DDT COA Number
DDT COA #000019

Instrument Name
Skin Infection Patient-Reported Outcome Measure (SKINFECT-PRO)

Disease/Condition
Acute Bacterial Skin and Skin Structure Infection

Concept of Interest
ABSSSI symptoms

Context of Use
Adult patients (> 18 years) with ABSSSI

COA Type
PRO

Qualification Stage
Letter of Intent-Accepted

Requestor(s)
Foundation for the National Institutes of Health (FNIH)

Contact(s)
Steve Hoffman
Kellee Howard

Date Accepted into CDER’s COA Qualification Program
March 1, 2013

Submission and Regulatory Correspondence History

Qualification Submission Date FDA Submission Decision & Recommendations Date
Update 2/3/17 FDA Response 11/20/17
Update 6/14/18 FDA Response 9/26/18
- - Transition Letter to 507 Process 9/5/19
Back to Top